FEV1/FVC <0.7 (GOLD) | FEV1/FVC <1.645 SD below predicted (ATS/ERS) | |||||
---|---|---|---|---|---|---|
Value | 95% CI | Value | 95% CI | |||
Physician-diagnosed COPD | Sensitivity | Women | 0.083 | 0.032–0.135 | 0.11 | 0.035–0.185 |
Men | 0.032 | 0–0.065 | 0.074 | −0.015–0.163 | ||
Specificity | Women | 0.996 | 0.993–1 | 0.995 | 0.991–0.999 | |
Men | 0.997 | 0.994–1 | 0.996 | 0.992–1 | ||
PPV | Women | 0.682 | 0.434–0.93 | 0.545 | 0.28–0.811 | |
Men | 0.545 | 0.17–0.921 | 0.364 | 0.001–0.726 | ||
NPV | Women | 0.918 | 0.903–0.934 | 0.952 | 0.94–0.964 | |
Men | 0.902 | 0.885–0.919 | 0.973 | 0.963–0.982 | ||
Chronic bronchitis symptoms | Sensitivity | Women | 0.044 | 0.006–0.083 | 0.073 | 0.011–0.136 |
Men | 0.048 | 0.009–0.088 | 0.074 | −0.015–0.163 | ||
Specificity | Women | 0.976 | 0.968–0.985 | 0.977 | 0.969–0.986 | |
Men | 0.983 | 0.975–0.991 | 0.981 | 0.973–0.989 | ||
PPV | Women | 0.154 | 0.029–0.279 | 0.154 | 0.029–0.279 | |
Men | 0.237 | 0.064–0.409 | 0.105 | −0.019–0.23 | ||
NPV | Women | 0.914 | 0.898–0.929 | 0.949 | 0.937–0.962 | |
Men | 0.902 | 0.885–0.92 | 0.972 | 0.963–0.982 |